The successful use of boston ocular surface prosthesis in the treatment of persistent corneal epithelial defect after herpes zoster ophthalmicus

Koray Gumus, Anisa Gire, Stephen C. Pflugfelder

Research output: Contribution to journalArticle

Abstract

PURPOSE:: To describe the use of the Boston ocular surface prosthesis (BOSP) to successfully treat a persistent corneal epithelial defect (PCED) after herpes zoster ophthalmicus that was minimally responsive to conventional therapies. METHODS:: A case report. RESULTS:: A 44-year-old man who developed a PCED in the right eye after herpes zoster ophthalmicus was treated with conventional therapies, including topical difluprednate opthalmic emulsion, 0.05% cyclosporine ophthalmic emulsion, topical autologous plasma, and oral doxycycline. Silicone plugs were inserted in the right upper and lower puncta. An 18-mm therapeutic hydrogel contact lens was placed in the right eye. After 4 weeks of this treatment, double layer amniotic membrane transplantation and temporary lateral tarsoraphy were performed. Ten days after the procedure, the amniotic membrane had dissolved and the tarsorrhaphy was opened. Because only partial healing of the corneal epithelial defect was observed, the patient was fit with the BOSP that he wore all waking hours. A soft contact lens was worn overnight after the BOSP was removed. Rapid reepithelization was observed within the week after starting the BOSP. The epithelial defect completely healed after 3 weeks, and the uncorrected visual acuity in the right eye improved to 20/50. CONCLUSIONS:: The BOSP should be considered as an important treatment option for management of PCEDs in eyes with altered corneal sensitivity.

Original languageEnglish (US)
Pages (from-to)1465-1468
Number of pages4
JournalCornea
Volume29
Issue number12
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Herpes Zoster Ophthalmicus
Artificial Eye
Amnion
Emulsions
Hydrophilic Contact Lens
Therapeutics
Doxycycline
Hydrogel
Contact Lenses
Silicones
Cyclosporine
Visual Acuity
Transplantation

Keywords

  • Boston ocular surface prosthesis
  • corneal sensitivity
  • herpes zoster ophthalmicus
  • persistent corneal epithelial defect

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The successful use of boston ocular surface prosthesis in the treatment of persistent corneal epithelial defect after herpes zoster ophthalmicus. / Gumus, Koray; Gire, Anisa; Pflugfelder, Stephen C.

In: Cornea, Vol. 29, No. 12, 12.2010, p. 1465-1468.

Research output: Contribution to journalArticle

@article{c7ee62210ac1466abc87296283133821,
title = "The successful use of boston ocular surface prosthesis in the treatment of persistent corneal epithelial defect after herpes zoster ophthalmicus",
abstract = "PURPOSE:: To describe the use of the Boston ocular surface prosthesis (BOSP) to successfully treat a persistent corneal epithelial defect (PCED) after herpes zoster ophthalmicus that was minimally responsive to conventional therapies. METHODS:: A case report. RESULTS:: A 44-year-old man who developed a PCED in the right eye after herpes zoster ophthalmicus was treated with conventional therapies, including topical difluprednate opthalmic emulsion, 0.05{\%} cyclosporine ophthalmic emulsion, topical autologous plasma, and oral doxycycline. Silicone plugs were inserted in the right upper and lower puncta. An 18-mm therapeutic hydrogel contact lens was placed in the right eye. After 4 weeks of this treatment, double layer amniotic membrane transplantation and temporary lateral tarsoraphy were performed. Ten days after the procedure, the amniotic membrane had dissolved and the tarsorrhaphy was opened. Because only partial healing of the corneal epithelial defect was observed, the patient was fit with the BOSP that he wore all waking hours. A soft contact lens was worn overnight after the BOSP was removed. Rapid reepithelization was observed within the week after starting the BOSP. The epithelial defect completely healed after 3 weeks, and the uncorrected visual acuity in the right eye improved to 20/50. CONCLUSIONS:: The BOSP should be considered as an important treatment option for management of PCEDs in eyes with altered corneal sensitivity.",
keywords = "Boston ocular surface prosthesis, corneal sensitivity, herpes zoster ophthalmicus, persistent corneal epithelial defect",
author = "Koray Gumus and Anisa Gire and Pflugfelder, {Stephen C.}",
year = "2010",
month = "12",
doi = "10.1097/ICO.0b013e3181da58b9",
language = "English (US)",
volume = "29",
pages = "1465--1468",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - The successful use of boston ocular surface prosthesis in the treatment of persistent corneal epithelial defect after herpes zoster ophthalmicus

AU - Gumus, Koray

AU - Gire, Anisa

AU - Pflugfelder, Stephen C.

PY - 2010/12

Y1 - 2010/12

N2 - PURPOSE:: To describe the use of the Boston ocular surface prosthesis (BOSP) to successfully treat a persistent corneal epithelial defect (PCED) after herpes zoster ophthalmicus that was minimally responsive to conventional therapies. METHODS:: A case report. RESULTS:: A 44-year-old man who developed a PCED in the right eye after herpes zoster ophthalmicus was treated with conventional therapies, including topical difluprednate opthalmic emulsion, 0.05% cyclosporine ophthalmic emulsion, topical autologous plasma, and oral doxycycline. Silicone plugs were inserted in the right upper and lower puncta. An 18-mm therapeutic hydrogel contact lens was placed in the right eye. After 4 weeks of this treatment, double layer amniotic membrane transplantation and temporary lateral tarsoraphy were performed. Ten days after the procedure, the amniotic membrane had dissolved and the tarsorrhaphy was opened. Because only partial healing of the corneal epithelial defect was observed, the patient was fit with the BOSP that he wore all waking hours. A soft contact lens was worn overnight after the BOSP was removed. Rapid reepithelization was observed within the week after starting the BOSP. The epithelial defect completely healed after 3 weeks, and the uncorrected visual acuity in the right eye improved to 20/50. CONCLUSIONS:: The BOSP should be considered as an important treatment option for management of PCEDs in eyes with altered corneal sensitivity.

AB - PURPOSE:: To describe the use of the Boston ocular surface prosthesis (BOSP) to successfully treat a persistent corneal epithelial defect (PCED) after herpes zoster ophthalmicus that was minimally responsive to conventional therapies. METHODS:: A case report. RESULTS:: A 44-year-old man who developed a PCED in the right eye after herpes zoster ophthalmicus was treated with conventional therapies, including topical difluprednate opthalmic emulsion, 0.05% cyclosporine ophthalmic emulsion, topical autologous plasma, and oral doxycycline. Silicone plugs were inserted in the right upper and lower puncta. An 18-mm therapeutic hydrogel contact lens was placed in the right eye. After 4 weeks of this treatment, double layer amniotic membrane transplantation and temporary lateral tarsoraphy were performed. Ten days after the procedure, the amniotic membrane had dissolved and the tarsorrhaphy was opened. Because only partial healing of the corneal epithelial defect was observed, the patient was fit with the BOSP that he wore all waking hours. A soft contact lens was worn overnight after the BOSP was removed. Rapid reepithelization was observed within the week after starting the BOSP. The epithelial defect completely healed after 3 weeks, and the uncorrected visual acuity in the right eye improved to 20/50. CONCLUSIONS:: The BOSP should be considered as an important treatment option for management of PCEDs in eyes with altered corneal sensitivity.

KW - Boston ocular surface prosthesis

KW - corneal sensitivity

KW - herpes zoster ophthalmicus

KW - persistent corneal epithelial defect

UR - http://www.scopus.com/inward/record.url?scp=78650517030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650517030&partnerID=8YFLogxK

U2 - 10.1097/ICO.0b013e3181da58b9

DO - 10.1097/ICO.0b013e3181da58b9

M3 - Article

C2 - 20847682

AN - SCOPUS:78650517030

VL - 29

SP - 1465

EP - 1468

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 12

ER -